key: cord-1036908-1ctim6w5
authors: Guan, Jingjing; Wei, Xin; Qin, Shuang; Liu, Xiaoyuan; Jiang, Yujie; Chen, Yingxiao; Chen, Yanfan; Lu, Hong; Qian, Jingjing; Wang, Zhongyong; Lin, Xiangyang
title: Continuous tracking of COVID-19 patients' immune status
date: 2020-09-25
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2020.107034
sha: b5ba002304c34b9885ecb9210dfe1846ea708e5e
doc_id: 1036908
cord_uid: 1ctim6w5

BACKGROUND: COVID-19 is threating human health worldwide. We aim to investigate the dynamic changes of immune status in COVID-19 patients with clinical evolution. METHODS: Sixty-one COVID-19 patients (42 mild cases and 19 severe cases, 51 cases without secondary infection as non-infection group and 10 cases with secondary bacterial/fungal infection as infection group) and 52 healthy controls (HCs) were enrolled from our hospital. Leucocyte classification, lymphocyte subsets and cytokines were detected by full-automatic blood cell analyzer and flow cytometer, respectively. RESULTS: Upon admission, eosinophils and lymphocyte subsets decreased significantly, while neutrophils, monocytes, basophils, IL-2, IL-6, IL-10 and IFN-γ increased significantly in COVID-19 patients compared to HCs. CD3(+) T and DN (CD3(+)CD4(-)CD8(-)) cells appeared sustained decline, leucocytes, neutrophils and IL-10 showed sustained increase in severe group compared to mild group. Compared with the non-infection group, we observed a depletion of eosinophils, CD3(+) T and CD4(+) T cells, but leucocytes, neutrophils, IL-6 and IL-10 on the contrary in the infection group. Besides, in severe group of COVID-19 patients, DN cells were negatively correlated with IL-10, and DP (CD3(+)CD4(+)CD8(+)) cells were negatively correlated with IL-6. Lymphocytes, eosinophils, CD3(+) T cells, CD4(+) T cells, IL-6 and IL-10 all had great diagnostic efficacy (AUC, 0.905-0.975) for COVID-19. The laboratory indicators of COVID-19 patients with improved condition also showed a recovery trend with time. CONCLUSIONS: The immune status of COVID-19 patients is different in each stage, and dynamic monitoring of related indicators can help predict the disease and may avoid cytokine storms.

In the past six months, coronavirus disease 2019 (COVID- 19) has become a global 46 epidemic that seriously threatens human health due to its high infectivity, high 47 mortality, and lack of directed antiviral drugs and vaccines. As of July 10, 2020, over 12 48 million people worldwide have been diagnosed with COVID-19 and 550384 people 49 have died from it, the mortality has increased from 3.7% reported in March to about can infect monocytes, macrophages and dendritic cells to promote the secretion of 66 cytokines, IL-6 can further activate the classic cis signal, trans signal and trans 67 presentation, resulting in multiple effects of acquired immune system (most 68 lymphocytes) and innate immune system (neutrophils, monocytes, NK cells, etc.) [5] . 69 However, due to the variability of SARS-CoV-2 and the complexity of human immune 70 regulatory network, the dynamic changes of immune status in mild and severe 71 COVID-19 patients are still controversial. In some COVID-19 patients, leucocytes and 72 neutrophils could even appear increased or declined, lymphocytes appeared normal, and 73 IL-10 was normal or elevated [7] . What's more, there are few reports on double positive 74 (CD3 + CD4 + CD8 + ) T cells (DP), double negative (CD3 + CD4 -CD8 -) T cells (DN) and 75 (CD3 + CD16 + /CD56 + ) NKT cells in COVID-19 patients. 76 We aim to analyze data derived from a designated hospital for referral severe 77 COVID- 19 115 We tested the COVID-19 patients' leucocyte classification, absolute value of 116 lymphocyte subsets and cytokines in 1-3 days (as soon as possible) after admission, and 117 based on the double-blind principle, we randomly selected 17-34 (40%-81%) mild 118 patients and 10-17 (56%-94%) severe patients (except the dead case) at the following 5 119 different period to detect the above indicators: 4-7 days, 8-10 days, 11-15 days, 16-20 120 days, 21-30 days (1-3 days before patients discharged from hospital) after patients 121 admission. At the same time, we tested cytokines of 52 enrolled HCs, then randomly 155 First, we conducted experimental analyses of the earliest collected specimens after 156 the enrolled patients admitted to our hospital. For leucocyte classification, we found that 157 compared with HCs, neutrophils, monocytes, and basophils were significantly 158 increased, and lymphocytes, eosinophils were significantly decreased, while leucocytes 159 had no statistical significance in COVID-19 patients ( Figure 2A ). The leucocytes and 160 neutrophils of the severe group were higher than the mild group, but lymphocytes, 161 monocytes, eosinophils and basophils did not differ between the two groups in 162 COVID-19 patients ( Figure 2B ). Interestingly, we found that in COVID-19 patients, 163 leucocytes and neutrophils in the infection group were also higher than those in the 164 non-infection group, while eosinophils were declined; lymphocytes, monocytes and 165 basophils were not markedly different between the two groups ( Figure 2C ). 166 Next, in the analysis of lymphocyte subsets, we found that compared with HCs, all indicators of COVID-19 patients showed a downward trend, especially CD3 + T, CD4 + 168 T, CD8 + T, DN and NKT cells (P < 0.0001) ( Figure 3A ). Among severe cases, only 169 CD3 + T and DN cells continued to decline compared with mild cases, although CD4 + T, 170 CD8 + T and NKT cells also showed a downward trend, there was no statistical 171 difference; B, NK and DP cells did not change significantly ( Figure 3B ). In COVID-19 172 patients with secondary infection, CD3 + T and CD4 + T cells were significantly lower 173 than those without infection, and other lymphocyte subsets were not statistically 174 different ( Figure 3C ). 175 Another interesting finding, the expression of IL-2, IL-6, IL-10 and IFN-γ in 176 COVID-19 patients was significantly higher than that of HCs, IL-4 and TNF-α didn't 177 seem to change significantly ( Figure 4A ). Then, we analyzed IL-2, IL-6, IL-10 and 178 IFN-γ between mild and severe COVID-19 patients, only the expression of IL-10 179 increased with the severity of the disease, no significant increase in IL-2, IL-6 and 180 IFN-γ ( Figure 4B ). However, compared with the non-infection group, we found that the 181 expression of IL-6 and IL-10 in the infection group was both significantly increased, 182 there was no significant difference in IL-2 and IFN-γ expression ( Figure 4C ). 184 To comprehend the connection among laboratory parameters which assess the 195 We used the above indicators to perform ROC curve analysis on the COVID- 19 and 196 HC groups, severe and mild groups, respectively. In terms of leucocyte classification 197 ( Figure 6A , can down-regulate the immune response, be resistant to activation-induced cell death, 304 and highly expresses perforin to regulate DN cell-mediated suppression, etc [19] . 305 Meanwhile, we found that IL-2, IL-6, IL-10 and IFN-γ in COVID-19 patients 

Coronavirus disease (COVID-19) outbreak 437 situation reports

Estimation of the basic reproduction number, average 440 incubation time, asymptomatic infection rate, and case fatality rate for COVID

Meta-analysis and sensitivity analysis

Vaccine designers take first shots at COVID-19

The current understanding and 446 potential therapeutic options to combat COVID-19, Life sciences

Cytokine release syndrome in severe COVID-19

Impaired immune cell cytotoxicity in severe 451

COVID-19 is IL-6 dependent

Mild versus severe COVID-19: Laboratory markers, 454 International journal of infectious diseases : IJID : official publication of the 1990

Extracellular Traps Drive Necroinflammation in COVID-19, Cells, 2020

Eosinophil responses during

COVID-19 infections and coronavirus vaccination

Clinical Characteristics of Coronavirus Disease 483 2019 in China

Viral and host factors related to the clinical 486 outcome of COVID-19

T cells found in coronavirus patients 'bode well' for long-term immunity

New differentiation pathway for 490 double-negative regulatory T cells that regulates the magnitude of immune responses

Longitudinal characteristics of lymphocyte responses and 493 cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Double positive

T cells are part of the adaptive immune response against Candida albicans

The clinical course and its correlated immune status in 499

COVID-19 pneumonia

Targeting Interleukin-6 Signaling 503 in Clinic

Therapeutic options for the 2019 novel coronavirus 505 (2019-nCoV)

Dysregulation of type I interferon responses in 508

Chloroquine enhances human CD8+

T cell responses against soluble antigens in vivo

Communicating Science in the Time of a Pandemic

Big studies dim hopes for hydroxychloroquine